Roche has secured early US approval for its oral breast cancer drug for patients, providing a new at-home treatment option for patients with advanced disease.
The US Food and Drug Administration (FDA) approved the drug in combination with everolimus, four weeks ahead of its target date for the application, as well as a companion blood test to identify suitable patients.
Targeting resistance to hormone therapy
Wilserdly (giredestrant) will be used for the treatment of locally advanced or metastatic breast cancer that is oestrogen receptor (ER)-positive and HER2-negative, and carries an ESR1 mutation.
ESR1 is the gene that encodes the oestrogen receptor. Mutations in the gene can allow the receptor to keep driving tumour growth even when treatments lower the amount of oestrogen available.
Wilserdly belongs to a class of drugs called selective oestrogen receptor degraders, or SERDs, which block the receptor and promote its breakdown. It is taken alongside everolimus, which targets a separate pathway involved in cell growth.
Eligible patients will include those whose cancer has returned during or after endocrine therapy following surgery or progressed after at least one endocrine treatment for metastatic disease. The paired blood test will identify patients whose tumours carry the specific mutations.
The FDA approval was based on positive results from the phase 3 evERA Breast Cancer trial which enrolled 373 adults, including 207 with ESR1-mutated tumours.
In that group, median progression-free survival was 10 months with Wilserdly and everolimus, compared with 5.5 months for patients who received a standard endocrine therapy with everolimus.
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial, according to Roche.
Overall survival data were still immature at the time of the analysis and common side effects with the Wilserdly combination included mouth inflammation, rash and fatigue.
Roche awaits separate decision on early-stage disease
The FDA is also reviewing Wilserdly as a treatment after surgery for patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of recurrence.
In the separate phase 3 lidERA trial, 92.4% of patients taking giredestrant were alive and free of invasive disease at three years, compared with 89.6% on standard endocrine therapy.
An approval would extend Wilserdly’s use to patients being treated to reduce the risk of their cancer returning after surgery. The FDA’s target date for that decision is 30 November.
Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development said: “For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge – often requiring more intensive treatment.
“By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home,” he added.
Featured image: Rafael Henrique on AdobeStock



